Rani Wins 180-Day Nasdaq Extension to May 10, 2027, Moves to Nasdaq Capital Market
RANI is trading near its 52-week low of $0.51 (3.0% above the low).
Summary
Nasdaq has given Rani until May 10, 2027 to regain the $1.00 minimum bid price and moved its listing to the Nasdaq Capital Market effective November 12, 2026. With the stock near $0.53, the company says a reverse split is among the options it may use to cure the deficiency.
Key Events · Legal and Risk Events · RANI
-
Nasdaq Grants 180-Day Extension
On November 10, 2026, Nasdaq granted an additional 180 calendar days, until May 10, 2027, to regain compliance with the $1.00 minimum closing bid price requirement.
-
Listing Moves to Capital Market
The transfer of the Class A common stock from The Nasdaq Global Market to The Nasdaq Capital Market took effect at the opening of business on November 12, 2026; the ticker remains RANI.
-
Compliance Requires 10 Straight Days Above $1.00
The closing bid price must be at least $1.00 per share for a minimum of 10 consecutive business days during the extension period, and Nasdaq may require up to 20.
-
Reverse Split Flagged as Possible Cure
Rani said it provided written notice of its intention to cure the deficiency, including by effecting a reverse stock split if necessary, and gave no assurance it will regain compliance.
Analysis · RANI · Life Sciences
The immediate delisting trigger is gone, but the deficiency is not. Rani had faced a November 9, 2026 deadline to lift its bid back above $1.00; Nasdaq has now given it until May 10, 2027 and shifted the listing to the Capital Market tier, buying roughly six more months of runway on the listing question. At about $0.53, the stock remains well below the $1.00 threshold, and the company has explicitly flagged a reverse stock split as a possible cure — a step that would reset the share count without changing the underlying business.
How filings like this one have moved
In the 30 days to Nov 12, 2026, 37% of the 3595 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, RANI was trading at $0.53 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $73.2M. The 52-week trading range was $0.51 to $2.16. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.